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Objectives This study sought to study stent thrombosis with the paclitaxel-eluting Taxus stent.
Background The incidence and timing of stent thrombosis after drug-eluting stent placement compared with bare-metal stent
implantation remain unsettled, with consequent uncertainty about risk stratification and long-term recommenda-
tions for antiplatelet medications.
Methods This study used a patient-based meta-analysis using the 4 principal TAXUS randomized trials (3,445 patients)
with a follow-up duration of 1 year.
Results Cumulative stent thrombosis occurred in 1.28%  0.31% in the Taxus group and 0.76%  0.23% in the bare-
metal stent group at 3 years (hazard ratio 1.51 [95% confidence interval 0.73 to 3.14], p  0.26). Hazard ratios
(per 100 patients per 6 months) were similar between the Taxus stent group (0.59 [95% confidence interval
0.22 to 0.95]) and the bare-metal stent group (0.64 [95% confidence interval 0.26 to 1.02]) through 6 months
during the prescribed clopidogrel period. However, from 6 months to 3 years there were more stent thromboses
in the Taxus group (hazard ratio 0.19 [95% confidence interval 0.06 to 0.32] vs. 0.02 [95% confidence interval
0.00 to 0.07], p  0.049). Of 8 patients with Taxus-related thrombosis after 6 months, 0 were taking clopidogrel
and 2 were not taking aspirin consistently. No Taxus-related stent thrombosis occurred after 2 years (922 pa-
tients thus far followed up for 3 years). Independent correlates of stent thrombosis were nonuse of clopidogrel,
male gender, smoking, and possibly use of multiple nonoverlapping stents.
Conclusions Approximately 0.8% of Taxus patients have stent thrombosis in the first 6 months after stent implantation, simi-
lar to bare-metal stents. However, a modest increase in risk is present with Taxus stents beyond 6 months, pos-
sibly because of inadequate antiplatelet drug therapy. (J Am Coll Cardiol 2007;49:1043–51) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.015l
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Ftent thrombosis after placement of a bare-metal stent
BMS) occurs in 1.0% to 1.9% of patients (1,2), typically
ithin the first month after stenting (2). Bare-metal stent
hrombosis has been related to stent underexpansion (3),
esidual dissection (1,4), low ejection fraction (4), stent
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aired response to antiplatelet therapy (7), and the stress of
oncardiac surgery (8), and results in myocardial infarction
r death in a high percentage of patients (1). Drug-eluting
tents (DES) provide clinical benefit by retarding smooth
oston Scientific Consultant/Advisory Board; Dr. Koglin holds Boston Scientific
wnership interest/stock; and Dr. Koglin is employed by Boston Scientific. Data
resented in part at the Transcatheter Cardiovascular Therapeutics Conference,
ctober 23 to 27, 2005, Washington, DC, and the American College of Cardiology
oundation Annual Scientific Session, March 11 to 14, 2006, Atlanta, Georgia.
Manuscript received July 26, 2006; revised manuscript received January 2, 2007,
ccepted January 9, 2007.
f
d
(
d
p
r
a
t
T
b
c
M
S
V
a
i
b
B
s
fi
b
t
d
d
d
o
c
t
T
T
r
a
D
i
a
o
a
t
d
w
t
d
d
t
t
(
i
t
c
S
s
r
s
w
b
e
c
w
t
p
l
t
t
d
i
f
s
o
a

I
*
1044 Ellis et al. JACC Vol. 49, No. 10, 2007
Early and Late Thrombosis With Taxus Stent March 13, 2007:1043–51muscle cell replication and extra-
cellular matrix production lead-
ing to restenosis, but may delay
endothelial healing and heighten
the risk of subsequent thrombo-
sis (9,10). Drug-eluting stent
thrombosis has been reported with
approximately similar incidence to
that with BMS (11,12), and in
addition to the aforementioned
actors, has been associated with premature antiplatelet therapy
iscontinuation, renal failure, bifurcation stenting, and diabetes
12). Occasional very delayed stent thrombosis has been
escribed (13). Previous studies examining the frequency and
redictors of stent thrombosis after use of a DES have been
estricted by modest sample size, limited follow-up duration,
nd often the lack of patient-level data. We therefore examined
he occurrence of stent thrombosis with the paclitaxel-eluting
axus stent (Boston Scientific, Natick, Massachusetts) and its
are metal equivalent from a large and very well-characterized
linical investigation population followed up for up to 3 years.
ethods
tudy population. The randomized TAXUS II, IV, V, and
I studies, conducted between June 2001 and March 2004,
nd previously described in detail (14–17), enrolled increas-
ngly complex patient and lesion populations to study the
enefit of Taxus stents compared with the otherwise identical
MS from which they were derived. Notably, patients pre-
enting with acute myocardial infarction, chronic renal insuf-
ciency, in-stent restenosis, lesions in diseased vein grafts,
ifurcations, lesions with ostial location, or lesions with visible
hrombus were consistently excluded. At the time of hospital
ischarge, aspirin 75 mg (324 mg in TAXUS IV and V)
aily was recommended indefinitely, and clopidogrel 75 mg
aily was recommended for at least 6 months. Characteristics
f the individual trials are provided in Table 1. Follow-up is
urrently available through 3 years for TAXUS II and IV,
hrough 2 years for TAXUS VI, and through 1 year for
AXUS V. One patient randomized to the control arm of
AXUS VI and who had a stent thrombosis on day 21 did not
ndividual Trial Characteristics
Table 1 Individual Trial Characteristics
TAXUS II
(n  529)
Geography 38 global sites
Stent platform NIRx
Formulation SR & MR
RVD (mm)* 3.0–3.5
Lesion length (mm)* 12
First patient enrolled June 29, 2001
Last patient enrolled January 14, 2002
Available follow-up (yrs) 3
Clinical status follow-up (n, %)† 513 (97.0%)
Abbreviations
and Acronyms
BMS  bare-metal stent
DES  drug-eluting stent
MACE  major adverse
cardiac event
TVR  target vessel
revascularizationRVD and lesion length inclusion criteria were based on visual estimates. †Includes patients who died.
MR  moderate-release; RVD  reference vessel diameter; SR  slow-release.eceive a study stent and therefore is excluded from this
nalysis.
efinitions. Stent thrombosis was consistently defined
n all trials as the occurrence of any of the following: 1)
n acute coronary syndrome with angiographic evidence
f thrombosis at the stented site; 2) in the absence of
ngiographic confirmation, acute myocardial infarction in
he distribution of the treated vessel; or 3) sudden cardiac
eath within the first 30 days of stent implantation
ithout other obvious cause. A Clinical Events Commit-
ee blinded to treatment assignment reviewed and adju-
icated all possible stent thrombosis-related events and
id override the definitions to assign a presumed stent
hrombosis to 1 case of sudden death after 30 days. Stent
hromboses were categorized as early (30 days) or late
30 days). In addition, the late cases were subdivided
nto a very late category (180 days), which corresponds
o the period beyond the protocol-mandated duration of
lopidogrel use.
tatistical methodology. Data are presented as mean 
tandard deviation. Between-group comparisons of event
ates were made using the Fisher exact test. Data for the
low- and moderate-release formulations of the Taxus stent
ere tested for between-group differences and were com-
ined for comparison with BMS when no apparent differ-
nces (p  0.10) were observed. Time-to-event data were
alculated with Kaplan-Meier methodology and compared
ith the log-rank test. Independent predictors of stent
hrombosis were determined using multivariate Cox pro-
ortional hazard regression models. Adjustments for base-
ine characteristics were made. Subjects who were alive at
he start of each time interval (defined for early stent
hrombosis as 30 days, late stent thrombosis as 30 to 180
ays, and very late stent thrombosis as 180 days) were
ncluded in the analysis group. Patients were not censored
rom inclusion in the later time periods if they had earlier
tent thrombosis, but stent thromboses were counted only
nce during each of the 3 time periods. Candidate variables
re listed in the footnote of Table 5. A 2-sided p value
0.05 was considered statistically significant. All modeling
US IV
1,314)
TAXUS V
(n  1,156)
TAXUS VI
(n  446)
. sites 66 U.S. sites 44 European sites
s Express2 Express
SR MR
75 2.25–4.0 2.5–3.75
10–46 18–40
29, 2002 February 27, 2003 May 10, 2002
2002 March 29, 2004 December 27, 2002
1 2
(94.4%) 1,112 (96.2%) 434 (97.3%)TAX
(n 
73 U.S
Expres
SR
2.5–3.
10–28
March
July 9,
3
1,241
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March 13, 2007:1043–51 Early and Late Thrombosis With Taxus Stentnalyses were performed using SAS version 9.1 (SAS
nstitute Inc., Cary, North Carolina).
esults
ncidence and timing of stent thrombosis. Of 3,445
andomized patients, 1,718 were assigned to paclitaxel-
luting stents and 1,727 to BMS. There were no differences
n the baseline clinical or angiographic characteristics be-
ween the 2 study groups (Table 2). There were also no
ifferences in the rates of use of aspirin and thienopyridine
gents at hospital discharge and during long-term follow-up
etween the 2 groups (Table 2). A total of 30 patients
0.87%, 30 of 3,445), including 12 (0.69%, 12 of 1,727) in
he BMS group and 18 (1.0%, 18 of 1,718) in the Taxus
roup (p 0.36) had a stent thrombosis through 3 years. As
hown in Figure 1, there were 17 early stent thromboses
rate of 0.49%, 17 of 3,445) and 13 late stent thromboses
rate of 0.38%, 13 of 3,445). Of the 13 late stent thrombosis
ases, 9 (rate of 0.26%, 9 of 3,445) occurred after 6 months,
nd are therefore considered very late.
Kaplan-Meier curves displaying freedom from stent
Baseline and Procedural Characteristics by Trea
Table 2 Baseline and Procedural Characteri
Cont
No. of patients 1,72
Age (yrs) 62.1 1
Male (%) 72.5
Diabetes, medically treated (%) 24.0
Current smoker (%) 21.5
Hyperlipidemia (%) 70.6
Hypertension (%) 68.0
Previous MI (%) 32.1
Unstable angina (%) 30.9
LAD location (%) 41.8
Mean RVD (mm) 2.73
Mean lesion length (mm) 15.11
Mean MLD (mm) 0.91
Total stented length (mm) 24.31
Stent:lesion length ratio 1.79
Multiple stents (%) 18.3
Overlapping (%) 28.3
Nonoverlapping (%) 71.7
Implantation pressure (atm) 13.40
Aspirin usage (%)
Discharge 99.4
1 month 98.7
4–6 months† 96.8
9 months‡ 96.4
Clopidogrel/ticlopidine usage (%)
Discharge 99.6
1 month 98.7
4–6 months† 92.9
9 months‡ 53.7
Numbers are percent of patients with characteristic or mean SD. *p-va
are from 2-sample t test. †TAXUS IV and TAXUS V de novo had a 4-mont
include a 9-month follow-up.
LAD  left anterior descending artery; MI  myocardial infarction;hrombosis are shown in Figure 2. There was no statisticalxcess in stent thromboses in the Taxus group compared
ith the BMS group over the entire 3-year follow-up period
r within the first 6 months (Kaplan-Meier event rates at 6
onths: 0.64% control and 0.58% Taxus, p  0.84; at 3
ears: 0.76% control and 1.28% Taxus, p  0.26). During
Figure 1 Breakdown of Stent Thrombosis by
Time and Type of Stent Received
MR  moderate release; SR  slow release; ST  stent thrombosis.
t
by Treatment
Taxus p Value*
1,718
62.3 10.9 0.62
72.1 0.79
23.2 0.60
22.4 0.56
70.3 0.85
69.4 0.36
33.5 0.42
32.4 0.38
41.8 1.00
2.74 0.51 0.88
15.19 7.91 0.76
0.90 0.35 0.95
24.61 11.25 0.42
1.80 0.81 0.86
19.4 0.41
28.5 0.96
71.5 0.96
13.39 2.82 0.84
99.6 0.35
99.0 0.43
97.7 0.13
97.1 0.33
99.9 0.07
98.8 0.66
94.2 0.11
55.1 0.45
categorical data are from Fisher exact test. p values for continuous data
-up; TAXUS II and TAXUS VI had a 6-month follow-up. ‡TAXUS II did not
minimum lumen diameter; RVD  reference vessel diameter.tmen
stics
rol
7
0.6
0.51
8.00
0.36
11.14
0.82
2.76
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Early and Late Thrombosis With Taxus Stent March 13, 2007:1043–51he prespecified very late period between 6 months and 3
ears, there were a total of 8 (0.47%, 8 of 1,718) stent
hromboses in the Taxus group and 1 (0.06%, 1 of 1,727) in
he BMS group (p  0.049), however. Of the 8 very late
tent thromboses occurring beyond 6 months in the Taxus
roup, 5 occurred in the slow-release group and 3 occurred
n the moderate-release group. Thus, the rate of very late
tent thrombosis was 0.37% (5 of 1,369) with the slow-
elease formulation and 0.86% (3 of 349) with the
oderate-release formulation (p  0.21).
Three-year freedom from all death and myocardial in-
arction was similar between the Taxus and control groups
97% vs. 97%, p  0.88; and 93% vs. 94%, p  0.96,
espectively). Three patients had multiple stent thrombosis:
Taxus patient at days 317 and 558, and 2 control patients
t days 1 and 4, and days 0.9 and 13.
orrelates of stent thrombosis. A comparison of baseline
emographics, lesion characteristics, and treatments ren-
ered between patients with (n  30) and without (n 
,415) stent thrombosis is provided in Table 3. Patients
ith stent thrombosis were more likely to be male, to have
ultiple nonoverlapping stents implanted, to smoke, and to
nitially present with unstable angina. As noted in Table 4,
lopidogrel or ticlopidine use at 1 month was less frequent
n patients with versus in those without stent thrombosis
88.5%, 23 of 26 vs. 98.8%, 3,343 of 3,384, respectively, p
.004). Reasons for not taking thienopyridines at 30 days in
atients with stent thrombosis were protocol violation (n 
), and diagnosis of gastric carcinoma shortly after the index
rocedure (n  1) and emergency colectomy at day 30 (n 
), both of which required antiplatelet therapy withdrawal.
n these 3 patients, stent thrombosis occurred on days 0, 5,
nd 38, respectively. Conversely, stent thrombosis devel-
ped in 3 of 43 patients (6.98%) who were not taking
lopidogrel or ticlopidine at 1 month, compared with 23 of
,366 patients (0.68%) who were taking clopidogrel or
Figure 2 Freedom From Stent Thrombosis for
Patients From TAXUS II, IV, V De Novo, and VI
Shown is event-free survival  1.5 SEM for all patients (n  3,445).iclopidine at 1 month (p  0.004).
aAt 4 to 6 months, this disparity in medication use was no
onger present, with 93.5% (3,156 of 3,374) of patients
ithout stent thrombosis and 90.0% (18 of 20) of stent
hrombosis patients taking thienopyridines (p 0.38). This
se decreased to 54.3% (1,504 of 2,772) in patients without
tent thrombosis and 76.9% (10 of 13) of stent thrombosis
atients at 9 months (p  0.16).
Univariate correlates of stent thrombosis during the
-year follow-up period were nonuse of clopidogrel/
iclopidine at hospital discharge, smoking, male gender,
ultiple nonoverlapping stents, age, and unstable angina at
nitial presentation (Table 5). Multivariate regression anal-
sis identified clopidogrel/ticlopidine nonuse, male gender,
nd smoking at the time of stent implantation, but not
axus stent implantation, as significant correlates for stent
hromboses occurring during the 3-year period. Notably,
lopidogrel/ticlopidine nonuse, smoking, and multiple non-
verlapping stents were significant predictors for early (30
ays) stent thrombosis.
The only independent correlate of late stent thrombosis
30 days) was a major adverse cardiac event (MACE)
ccurring within 30 days of the original procedure (1 Taxus
atient with stent thrombosis on day 408 had a Q-wave
yocardial infarction on day 0, and a second Taxus patient
ith stent thrombosis on day 519 had a Q-wave myocardial
nfarction on day 1). A weak trend was present toward
axus stent use as an independent predictor of late stent
aseline and Proceduralharacteristics by Stent Thrombosis
Table 3 Baseline and ProceduralCharacteristics by Stent Thrombosis
No Stent
Thrombosis
Stent
Thrombosis p Value*
Number of patients 3,415 30
Age (yrs) 62.3 10.7 59.1 12.2 0.11
Male (%) 72.1 93.3 0.01
Diabetes, medically
treated (%)
23.6 26.7 0.67
Current smoker (%) 22.2 41.4 0.01
Hyperlipidemia (%) 70.9 69.0 0.84
Hypertension (%) 69.0 60.0 0.32
Previous MI (%) 33.1 40.0 0.44
Unstable angina (%) 31.5 48.3 0.07
LAD location (%) 41.9 43.3 0.86
Mean RVD (mm) 2.74 0.51 2.72 0.53 0.90
Mean lesion length (mm) 15.15 7.97 14.99 7.13 0.91
Mean MLD (mm) 0.90 0.36 0.90 0.29 0.98
Total stented length
(mm)
24.46 11.22 23.98 9.41 0.81
Stent:lesion length ratio 1.80 0.82 1.82 0.72 0.86
Multiple stents (%) 19.9 26.7 0.36
Overlapping (%) 28.4 16.7 0.53
Nonoverlapping (%) 6.7 20.0 0.01
Implantation pressure
(atm)
13.39 2.79 13.73 2.50 0.51
umbers are percent of patients with characteristic or mean  SD. *p values for categorical data
re from Fisher exact test. p values for continuous data are from 2-sample t test.
Abbreviations as in Table 2.
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o 10.69], p  0.11).
Considering very late stent thrombosis (6 months to 3
ears), however, use of a Taxus stent was correlated with
edication Usage of Patients With and Without Stent Thrombosis
Table 4 Medication Usage of Patients With and Without Stent
No Stent
Thrombosis
(n  3,415)
Stent T
(Ov
(n
Aspirin usage (%)
Discharge 99.4 1
(3,395/3,414) (3
1 month 98.9 9
(3,346/3,384) (2
4–6 months§ 97.2 1
(3,281/3,374) (2
9 months 96.7 1
(2,681/2,772) (1
Clopidogrel/ticlopidine usage (%)
Discharge 99.8 9
(3,406/3,414) (2
1 month 98.8 8
(3,343/3,384) (2
4–6 months§ 93.5 9
(3,156/3,374) (1
9 months 54.3 7
(1,504/2,772) (1
p value compares no stent thrombosis versus stent thrombosis overall using the Fisher exact test.
s defined as occurring 30 days after stent implantation. §TAXUS IV and TAXUS V de novo had a
ollow-up.
nivariate and Multivariate Predictors of Stent Thrombosis
Table 5 Univariate and Multivariate Predictors of Stent Thromb
Parameter
Univariate
Hazard Ratio (95% CI)
All stent thrombosis (n  30)
Clopidogrel/ticlopidine use at discharge 0.06 (0.01–0.47)
Current smoking 2.47 (1.18–5.17)
Male 5.32 (1.27–22.33)
Multiple non-overlapping stents 2.68 (1.03–7.01)
Age 0.97 (0.93–1.00)
Unstable angina 2.02 (0.97–4.18)
Taxus stent 1.51 (0.73–3.14)
Early stent thrombosis (n  17)*
Clopidogrel/ticlopidine use at discharge 0.03 (0.00–0.26)
Multiple non-overlapping stents 5.77 (2.03–16.36)
Current smoking 3.49 (1.31–9.30)
Male 6.15 (0.82–46.34)
Taxus stent 0.89 (0.35–2.32)
Late stent thrombosis (n  13)†
MACE within 30 days post-procedure 5.63 (1.25–25.42)
Unstable angina 3.01 (0.96–9.49)
Taxus stent 3.37 (0.93–12.24)
ll p values are from Cox proportional hazard model. *Early stent thrombosis is defined as occurring
mplantation.Variables tested in models: patient characteristics age, gender, diabetes, clopidogrel/
ypertension, left anterior descending artery as target vessel, previousmyocardial infarction, unstable a
ength (angiography), reference vessel diameter (angiography), minimum lumen diameter pre-proc
ost-procedure (angiography), multiple stenting, multiple overlapping stenting, multiple nonoverlap
ost-procedure (intravascular ultrasound).
MACE  major adverse cardiac event.xcess risk (hazard ratio 8.09 [95% confidence interval 1.01
o 64.67], p  0.021). No Taxus-related thrombosis oc-
urred in the 922 patients followed up beyond 2 years thus
ar.
mbosis
osis
p Value*
Early Stent
Thrombosis†
(n  17)
Late Stent
Thrombosis‡
(n  13)
1.0000 100.0 100.0
(17/17) (13/13)
0.0349 92.3 92.3
(12/13) (12/13)
1.0000 100.0 100.0
(9/9) (11/11)
1.0000 100.0 100.0
(7/7) (6/6)
0.0677 94.1 100.0
(16/17) (13/13)
0.0040 84.6 92.3
(11/13) (12/13)
0.3756 100.0 81.8
(9/9) (9/11)
0.1609 71.4 83.3
(5/7) (5/6)
tent thrombosis is defined as occurring30 days after stent implantation. ‡Late stent thrombosis
h follow-up; TAXUS II and TAXUS VI had a 6-month follow-up. TAXUS II did not include a 9-month
tors Multivariate Predictors
p Value Hazard Ratio (95% CI) p Value
0.0069 0.07 (0.01–0.50) 0.009
0.0165 2.26 (1.06–4.81) 0.035
0.0224 10.18 (1.38–75.03) 0.023
0.0442 2.04 (0.97–4.30) 0.062
0.0449
0.0593
0.2671 1.61 (0.75–3.47) 0.222
0.0011 0.04 (0.01–0.38) 0.004
0.0010 3.79 (1.17–12.27) 0.026
0.0124 3.32 (1.20–8.65) 0.021
0.0781
0.8191 1.11 (0.41–3.05) 0.833
0.0248 5.34 (1.16–24.49) 0.031
0.0597 2.86 (0.91–9.03) 0.073
0.0650 2.89 (0.78–10.69) 0.112
ays after stent implantation. †Late stent thrombosis is defined as occurring 30 days after stent
ne and aspirin use at discharge and 1 month, GP IIb/IIIa inhibitor use periprocedural, hyperlipidemia,
moking, and type C lesion; procedural/lesion characteristics total stent length (site reported), lesion
angiography), minimum lumen diameter post-procedure (angiography), percent diameter stenosis
nting, minimum stent area post-procedure (intravascular ultrasound), and minimum lumen areaThro
hromb
erall)
 30)
00.0
0/30)
2.3
4/26)
00.0
0/20)
00.0
3/13)
6.7
9/30)
8.5
3/26)
0.0
8/20)
6.9
0/13)
†Early sosis
Predic
30 d
ticlopidi
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edure (
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Characteristics of Patients With Early and Late Stent Thrombosis*
Table 6 Characteristics of Patients With Early and Late Stent Thrombosis*
Patient #
Stent
Type
Age (yrs),
Gender Smoking
Unstable
Angina
Days
to ST
Angiographically
Confirmed
Treated
Vessel
Stent
Diameter
(mm)
Stent
Length
(mm) Medication Status Clinical Sequelae
Death
(Immediate
or In
Hospital)
ST
Caused
Death
1 Taxus SR 50, male Yes Yes 0 Yes RCA 3.5 15 ASA: none NQWMI, TLR No No
Clopidogrel: none
2 Taxus SR 50, male Yes Yes 0 Yes LAD 3.0 32 ASA: 325 mg NQWMI, TLR No No
Clopidogrel: none
3 Taxus SR 52, male Yes No 1 Yes RCA 3.5 36 ASA: 325 mg QWMI, TLR No No
Clopidogrel: 75 mg
4 Taxus SR 68, male No No 2 Yes CX 2.25 20 ASA: 325 mg TLR No No
Clopidogrel: 75 mg
5 Taxus SR 48, male Yes No 5 Yes CX 3.5 40 ASA: 325 mg NQWMI, TLR No No
Clopidogrel: 75 mg
6 Taxus MR 68, male Yes Yes 6 Yes CX 2.5 24 ASA: 80 mg NQWMI, TLR No No
Clopidogrel: 75 mg
7 Taxus SR 41, male No Yes 7 No CX 3.0 32 ASA: 325 mg Cardiac death Yes Yes
Clopidogrel: 75 mg
8 Taxus SR 77, male No Yes 7 No LAD 2.5 24 ASA: 325 mg Cardiac death Yes Yes
Clopidogrel: 75 mg
9 Taxus SR 51, male No No 38 Yes LAD 3.0 32 ASA: none QWMI, TLR, cardiac
death
No No
Clopidogrel: none, stopped 4 days prior
10 Taxus SR 62, male No No 48 Yes LAD 3.5 32 ASA: none QWMI No No
Clopidogrel: none, stopped 7 days prior
11 BMS 65, male No No 0 Yes RCA 3.5 16 ASA: 325 mg NQWMI, cardiac
death
Yes Yes
Clopidogrel: loading dose day of
procedure/event
12 BMS 70, male No Yes 1 Yes LAD 3.0 48 ASA: 325 mg QWMI, TLR Yes Yes
Clopidogrel: 75 mg
13 BMS 75, male No No 22 Yes CX 2.5 16 ASA: 325 mg QWMI, TLR No No
Clopidogrel: 75 mg
14 BMS 83, male No No 22 No CX 3.0 16 ASA: 325 mg Cardiac death No Yes
Clopidogrel: 75 mg
15 BMS 40, male No Yes 74 Yes CX 2.5 24 ASA: 325 mg NQWMI No No
Clopidogrel: 75 mg
16 BMS 42, male Unknown No 0 Yes LAD 2.5 16 ASA: 325 mg NQWMI, TLR No No
Clopidogrel: 75 mg
17 BMS 45, female Yes Yes 8 Yes CX 2.25 16 ASA: 325 mg only on morning ST NQWMI, TLR No No
Clopidogrel: none
18 BMS 66, male No No 8 Yes LAD 2.5 16 ASA: 325 mg QWMI, TLR No No
Clopidogrel: 75 mg
19 BMS 66, male No No 75 No LAD 3.0 20 ASA: 325 mg Cardiac death No No
Clopidogrel: 75 mg
20 BMS 64, male Yes No 0 Yes RCA 3.0 24 ASA: 325 mg TLR, non-TVR No No
Clopidogrel: 75 mg post-procedure
21 BMS 45, male Yes No 20 No LAD 3.0 32 ASA: None NQWMI No No
Clopidogrel: none
*Early stent thrombosis is defined as any stent thrombosis occurring 30 days; Late stent thrombosis is defined as any stent thrombosis occurring 31 to 180 days.
ASA  aspirin; CX  circumflex; NQWMI  non–Q-wave myocardial infarction; QWMI  Q-wave myocardial infarction; RCA  right coronary artery; ST  stent thrombosis; TLR  target lesion revascularization; TVR  target vessel revascularization; other abbreviations
as in Tables 1 and 2.
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March 13, 2007:1043–51 Early and Late Thrombosis With Taxus Stentlinical consequences of early and late stent thrombosis
ccurring up to 6 months after stenting. Early stent
hrombosis resulted in 30-day rates of death in 29.4% (5 of
7) of patients, myocardial infarction in 76.5% (13 of 17),
nd target vessel revascularization (TVR) in 70.6% (12 of
7). The overall mortality of patients with early stent
hrombosis was 41.2% (7 of 17), with a median follow-up
uration after stent thrombosis of 6.2 months versus 3.2%
108 of 3,428) in patients without stent thrombosis (median
ollow-up duration of 25.9 months).
The clinical correlates, timing, aspirin and clopidogrel
se, and consequences of the 20 stent thromboses that
ccurred 180 days after stent implantation are listed in
able 6. There were 2 BMS patients and 2 Taxus patients
ith stent thrombosis between 30 days and 6 months
fter stenting. Of these 4 patients, 2 patients (50.0%)
ied, 3 patients (75.0%) had a myocardial infarction, and
patient (25.0%) had a TVR. A 66-year-old man who
eceived a BMS died suddenly 75 days after stent
mplantation. Because no autopsy was performed, the
ccurrence of stent thrombosis was presumed by the
linical events committee. A 51-year-old male Taxus
low-release patient who had a Q-wave myocardial in-
arction and angiographically confirmed stent thrombosis
haracteristics of Patients With Very Late Stent Thrombosis*
Table 7 Characteristics of Patients With Very Late Stent Throm
Patient #
Stent
Type
Age (yrs),
Gender Smoking
Unstable
Angina
Days
to ST
1 Taxus MR 56, male Yes Yes 317
2 Taxus SR 72, male No Yes 341
3 Taxus MR 79, male No Yes 408
4 Taxus SR 53, male Yes Yes 498
5 Taxus SR 57, male No Yes 519
6 Taxus SR 59, male No Yes 522
7 Taxus SR 45, male Yes No 711
8 Taxus MR 54, female No No 743
9 BMS 44, male Yes No 988
Very late stent thrombosis is defined as any stent thrombosis occurring after 180 days.
BMS  bare-metal stent; PCI  percutaneous coronary intervention; other abbreviations as in T8 days after the index procedure died during attempted tVR. Both aspirin and clopidogrel therapy had been
iscontinued for 4 days before the stent thrombosis for
lanned surgery.
escription of patients with very late stent thrombosis
eyond 6 months. The clinical correlates, timing, aspirin
nd clopidogrel use, and consequences of the 9 very late
tent thromboses (6 months after stent implantation) are
isted in Table 7. Eight Taxus patients and 1 BMS patient
ad a very late stent thrombosis (between days 317 and
88). No stent thrombosis occurred beyond 743 days in
axus-treated patients. No patient was taking clopidogrel at
he time of stent thrombosis. One patient had discontinued
spirin as well for surgery, whereas a second patient only
sed aspirin occasionally. At the time of stent thrombosis,
yocardial infarctions occurred in 8 of the 9 patients
88.9%) with late stent thrombosis, including 7 Q-wave and
non–Q-wave infarctions, but none died. Six patients
nderwent a target lesion revascularization, and a seventh
atient had a re-intervention remote from the target lesion
TVR rate 77.8%).
Seven of the 9 late stent thrombosis patients did not
xperience any further MACE after their thrombotic event
with median follow-up of 548 days). One Taxus moderate-
elease patient had an additional Q-wave myocardial infarc-
s*
raphically
firmed
Treated
Vessel
Stent
Diameter
(mm)
Stent
Length
(mm) Medication Status
No CX 3.0 15 ASA: 100 mg
Clopidogrel: stopped 163 days
before
No LAD 3.5 15 ASA: 75 mg
Clopidogrel: stopped 180
days before
Yes LAD 3.0 40 ASA: 75 mg
Clopidogrel: stopped 251 days
before
Yes LAD 2.5 16 ASA: 325 mg, poor compliance
Clopidogrel: stopped 228 days
before
Yes RCA 3.5 32 Both ASA and clopidogrel
stopped 5–8 days before
surgery
Yes RCA 3.5 15 ASA: 160 mg
Clopidogrel: stopped 363 days
before
Yes RCA 3.5 16 ASA: 325 mg
Clopidogrel: stopped 42 days
before
No RCA 3.0 15 ASA: 75 mg
Clopidogrel: stopped 583 days
before
Yes RCA 3.5 15 ASA: 100 mg
Clopidogrel: stopped 800
days beforebosi
Angiog
Con
able 6.ion and stent thrombosis 241 days after the first stent
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Early and Late Thrombosis With Taxus Stent March 13, 2007:1043–51hrombosis. Additionally, 1 Taxus slow-release patient died
f cardiac causes 225 days after the stent thrombosis.
iscussion
he principal findings of this large meta-analysis of the
rospective, double-blind, randomized controlled trials of
axus paclitaxel-eluting stents versus BMS are as follows: 1)
here seems to be no difference between the rates of stent
hrombosis with the Taxus stent compared with its bare
etal equivalent stent through approximately 6 months
incidence approximately 0.8% in both groups). 2) Between
months and 2 years an approximately 0.4% absolute excess
isk of stent thrombosis with the Taxus stent was observed.
o stent thromboses occurred in 900 Taxus-treated
atients followed up from postimplantation year 2 to year 3.
) The risk of stent thrombosis seems to be associated with
hienopyridine nonuse at the time of hospital discharge,
ale gender, smoking, and possibly the use of multiple
onoverlapping stents. Furthermore, there seems to be no
ignificant difference in risk between the slow-release and
oderate-release formulations of the Taxus stent, although
he study sample was underpowered to detect small differ-
nces. Because only the slow-release formulation (which
eleases 3 times less paclitaxel than the moderate-release
ormulation) is commercially available, larger studies are
equired to define more accurately the point estimate of late
tent thrombosis with the moderate-release stent. The
esults of multivariate analyses should be considered with
aution because of the relatively small numbers of patients
ith stent thrombosis. 4) The consequences of stent throm-
osis occurring either early or late after implantation remain
rave with both DES and BMS, with high rates of death,
yocardial infarction, and repeat revascularization.
The incidence of Taxus-related early stent thrombosis in
his study perhaps is modestly higher than, but generally in
ine with, that found by Moreno et al. (11) in their
eta-analysis of DES. This difference likely reflects the
onsiderably longer lesions and increased complexity in
atients enrolled in the Taxus V and VI studies (which were
ot included in the review by Moreno et al. [11]) (16,17),
nd possibly differences in the definition of stent thrombosis
etween studies (15,18). The modest number of patients (n
9) with very late (6 months) stent thrombosis makes
ssessment of correlations difficult, and the results should be
onsidered speculative and hypothesis generating. Certainly,
he absence of clopidogrel therapy in all patients developing
ery late stent thrombosis is notable. However, it should be
oted that the frequency of aspirin and clopidogrel use was
ot collected in patients without MACE after 9 months; as
uch, determination of the exact relationship between late
ntiplatelet agent usage and late stent thrombosis is not
ossible from this study. Patients surviving stent thrombosis
lso may have had their duration of therapy extended in
ttempt to prevent further events. The possible etiologic
ole of antiplatelet agent hyporesponsiveness in stent thrombosis also is not addressed by the present report. In
his regard, studies relating patient “resistance” to aspirin
nd/or clopidogrel are provocative, but not yet definitive
7,19).
The results of the present study are important to consider
n light of 2 recent reports. The BASKET-LATE (BAsel
tent Kosten Effektivitäts Trial—Late Thrombotic Events)
andomized trial of drug-eluting stents versus BMS showed
hat for 746 patients who were MACE-free at 6 months,
he incidence of late stent thrombosis between 6 and 18
onths tended to be greater in patients assigned to
irolimus-eluting or paclitaxel-eluting stents rather than to
MS (2.6% vs. 1.3%, p  0.23) (20). Secondly, investiga-
ors from the multicenter observational PREMIER (Pre-
ention of Myocardial Infarction Early Remodeling) regis-
ry documented that 13.6% of 500 patients receiving DES
iscontinued clopidogrel within 30 days, a finding associ-
ted with a 10-fold increase in mortality at 1 year (21).
hese 2 studies suggest that the frequency of premature
hienopyridine discontinuation and subsequent stent
hrombosis may be even more prevalent in an unregulated,
eal-world environment than in highly controlled, random-
zed, clinical trials.
The devastating complications of stent thrombosis
1,2), together with the possible correlation of very late
tent thrombosis with the absence of dual antiplatelet
herapy, might make one consider prolonging the routine
uration of poststent clopidogrel. However, that consid-
ration must be balanced against the lack of firm knowl-
dge, the bleeding risks (22), and the costs associated
ith clopidogrel use. Platelet hyper-reactivity in the
etting of hyperadrenergic states may also contribute to
tent thrombosis. In this regard, antiplatelet agents were
orced to be discontinued in some patients because of the
eed for surgery or hemorrhagic complications, after
hich stent thrombosis occurred. It is not clear that such
ituations could be avoided by recommendation of uni-
ersal prolonged usage of a dual antiplatelet regimen.
learly, more research is necessary to understand the
elationship between aspirin and clopidogrel use, anti-
latelet agent hyporesponsiveness (resistance), and the
isk of stent thrombosis.
The rate of stent thrombosis is dependent on the defini-
ions used. The current definitions might overestimate stent
hrombosis as far out as 30 days and underestimate stent
hrombosis after 30 days. Moreover, varying definitions of
tent thrombosis have been used in studies evaluating other
non–paclitaxel-based) DES, and as such, comparison of
hese results with other trials is difficult. An optimized
ndustry-standard definition is urgently needed. Nonetheless,
t is of note that an excess rate of very late stent thrombosis
f approximately 0.5% through 3 years has also been
eported with the sirolimus-eluting stent compared with its
are metal equivalent in a similar meta-analysis of 4 pivotal
rials with that device, at least using some definitions (23).
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March 13, 2007:1043–51 Early and Late Thrombosis With Taxus StentThis analysis is principally limited by the modest number
f patients with stent thrombosis, uncertainties regarding
rug treatment beyond 1 year after stenting for patients
ithout stent thrombosis, and lack of definite dates of
ntiplatelet agent discontinuation. The results from ran-
omized trials also do not apply to all real-world applica-
ions, even when increasingly complex patients and lesions
re included, as in the present study. Additionally, the
azard ratio for very late stent thrombosis (6 months to 3
ears) for the Taxus stent, 8.09 [95% confidence interval
.01 to 64.67, p  0.049], was calculated with the deaths
efore 6 months (n  33) removed from the risk set, those
ost to follow-up before 6 months (n  36) removed from
he data set, and the patients with treated stent thrombosis
efore 6 months (n 21) retained in the data set. Thus, this
azard ratio and its associated p value were not based on the
ull randomization groups and should be interpreted as
pproximate.
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